FOLFIRI-ramucirumab (FOLFIRI-Ram) versus ramucirumab-paclitaxel (Ram-Pac) in the second line (2L) for patients with advanced upper gastrointestinal (UGI) cancer: A real-world propensity-score matched analysis of survival.doi:10.1200/JCO.2025.43.4_suppl.377...
Further research, culminating in several phase 3 studies in multiple tumour types, confirmed the efficacy of ramucirumab. The inhibition of the VEGFR-2 receptor in second-line treatment for advanced gastric cancer improved survival when given alone or in combination with paclitaxel18, 19 and for non...
Ramucirumab was first approved to treat advanced or metastatic gastric orgastroesophageal junction(GEJ) cancer whose disease had progressed during or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy[39, 40], which was on the basis of a multinational randomized double-blind...
Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least one platinum- an...
RamucirumabThird linePurposeFew data described the activity of chemotherapy after ramucirumab plus paclitaxel progression in metastatic gastric cancer patients. The aim of this phase II study is to assess the efficacy...doi:10.1007/s10637-019-00725-3Roviello, Giandomenico...
Ramucirumab/paclitaxel represents an active combination in the management of gastric cancer. SWOG 1922 evaluates the use of FOLFIRI or ramucirumab/paclitaxel in the second- and later-line setting for small bowel adenocarcinoma. Methods: This is randomized, phase II, selection design clinical trial of...
Background Previous studies demonstrated that the combination of chemotherapy with ramucirumab allows to improve the treatment results in advanced gastric cancer (GC). The one of the available options for the second line chemotherapy is combination of irinotecan with fluoropyrimidines. As angiogenesis ...